Riociguat NEW
| Price | $36 | $58 | $100 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Riociguat | CAS No.: 625115-55-1 |
| Purity: 99.91% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Riociguat |
| Description | Riociguat (BAY 632521) is a stimulator of guanylate cyclase which causes relaxation of vascular smooth muscle and is used to treat severe pulmonary arterial hypertension. |
| In vitro | BAY 63-2521 (Riociguat) concentration-dependently stimulates the recombinant soluble guanylate cyclase (sGC) from 0.1 to 100 μM, resulting in a two-fold to 73-fold increase, through an NO-independent but haem-dependent mechanism. [1] Additionally, Riociguat impairs platelet function in isolated platelets, though it does not affect platelets in whole blood, nor does it directly influence the contractility and relaxation of cardiac myocytes. [2] [3] |
| In vivo | In a long-term study, Riociguat (10 mg/kg/d, orally) was found to partially mitigate pulmonary arterial hypertension, right heart hypertrophy, and structural remodeling of lung vasculature in hypoxic mice and monocrotaline (MCT)-injected rats. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40.83 mg/mL (96.66 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.73 mM), Sonication is recommended. |
| Keywords | Riociguat | Inhibitor | inhibit | Guanylatecyclase | guanylate cyclase | BAY-632521 | BAY632521 |
| Inhibitors Related | LY83583 | Lificiguat | Zagociguat | Sinitrodil | NPR-C activator 1 | Nelociguat | Nitroprusside disodium dihydrate | NS-2028 | Indusatumab | Methylene Blue | Methylene Blue trihydrate | Cinaciguat |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-17 | ||
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-07-17 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-17 | ||
| $30.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-09 | |
|
Moxin Chemicals
|
2025-12-16 | |||
|
VIP7Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2025-12-15 | ||
| $1.00 |
Qiuxian Baitai New Material Co., LTD
|
2021-11-27 | ||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 | ||
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-09 | ||
| $1.00 |
HubeiwidelychemicaltechnologyCo.,Ltd
|
2019-10-30 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY